- Home
- GNS vs ATRA Comparison
GNS vs ATRA Comparison
Compare GNS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | ATRA |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 38.9M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GNS | ATRA |
|---|---|---|
| Price | $0.46 | $5.15 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 906.2K | 90.8K |
| Earning Date | 03-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | N/A |
| P/E Ratio | ★ N/A | $1.90 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $3.92 |
| 52 Week High | $1.92 | $19.15 |
Technical Indicators
Market Signals| Indicator | GNS | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 51.10 |
| Support Level | $0.36 | $4.14 |
| Resistance Level | $0.48 | $5.55 |
| Average True Range (ATR) | 0.04 | 0.45 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 88.53 | 83.81 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).